TUCSON, AZ--(Marketwire - December 06, 2011) - CDEX Inc. (OTCBB: CEXI), a leading developer of chemical detection products using patented technologies for use in healthcare, safety and security markets, today demonstrated its recently launched ValiMed™ G4 multi-component medication and narcotic detection system at the 46th Annual Midyear ASHP Clinical Meeting and Exhibition. The ASHP conference is being held at the New Orleans Ernest N. Morial Convention Center in New Orleans, Louisiana, December 4-8, 2011. The ValiMed™ G4 will be showcased at booth 247 at the conference.
The ValiMed G4 drug validation system helps healthcare providers ensure patient safety and control costs by reducing medication errors. The patented detection process identifies drug strengths and volume-by-weight in real-time, validating proper dose, diluents and concentration of high-risk compounded medications and treatment solutions. The VG4 device will help healthcare facilities comply with Joint Commission compliance requirements and USP 797 guidelines for compounding sterile preparations (CSPs), and will integrate with electronic medical record (EMR) platforms.
"With the recent launch and commercial production of our ValiMed™ G4 system, we are excited to showcase the system at the ASHP Midyear conference, where a national and international audience of industry professionals will witness the power of our technology. We are the first to commercialize an affordable advanced measuring system, with multi-component capabilities that will enhance and improve the quality of care that pharmacies and clinical professionals provide. The conference should provide an optimum platform for our ValiMed G4 to gain market penetration and build industry buzz for our system. We expect to deliver several units over the next six months as the market interest continues to spread for the VG4," stated Jeff Brumfield, chairman and chief executive officer of CDEX.
CDEX's VG4 significantly raises the bar for patient medication safety and pharmaceutical drug loss prevention. The ValiMed G4 provides cutting edge features and benefits over existing systems available in the market. In addition to validating high-risk medications before leaving the clinical or pharmacy environment, the ValiMed G4 will also monitor and discourage the diversion of controlled substances by validating the returned or unused narcotics from patient treatment areas or surgery suites. Other applications for the ValiMed G4 system include counterfeit medication monitoring, regulatory compliance and training of clinical and pharmacy personnel.
The American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting and Exhibition is the largest gathering of pharmacists in the world. With its focus on improving patient care, the conference is attended by more than 20,000 pharmacy professionals from 86 countries. For over four decades, the ASHP Midyear Clinical Meeting has provided health-system pharmacy practitioners with a venue for updating their knowledge, networking with colleagues, enhancing their skills, and learning about the latest products and technologies available in the market. For more information about the event please visit: http://www.ashp.org/Midyear2011.
CDEX develops, manufactures and globally distributes products to the healthcare, safety and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and pharmacy returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets in the future where its proprietary products can be launched. To learn more about CDEX please visit: www.cdex-inc.com.
Safe Harbor Statement
Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans," "may," "believes," "should," "intends," and similar words. These statements pose risks that cannot be accurately predicted. Consequently, results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.